Suppr超能文献

利妥昔单抗成功用于一例对泼尼松和他莫昔芬治疗耐药的Riedel甲状腺炎病例。

SUCCESSFUL USE OF RITUXIMAB IN A CASE OF RIEDEL THYROIDITIS RESISTANT TO TREATMENT WITH PREDNISONE AND TAMOXIFEN.

作者信息

Mammen Saira Varghese, Gordon Murray B

出版信息

AACE Clin Case Rep. 2019 Apr 25;5(3):e218-e221. doi: 10.4158/ACCR-2018-0352. eCollection 2019 May-Jun.

Abstract

OBJECTIVE

Riedel thyroiditis (RT) is a rare disorder with high morbidity and limited treatment options. We describe a case resistant to conventional treatment with corticosteroids and tamoxifen, which subsequently responded to rituximab.

METHODS

Surgical pathology with hematoxylin and eosin staining was initially performed to confirm diagnosis, followed by IgG4 immunostaining and IgG4 serology in the setting of refractory RT, given its association with IgG4-related disease. Response to treatment was monitored subjectively as well as objectively with serial computed tomography scans.

RESULTS

A 51-year-old female with history of Hashimoto thyroiditis presented with compressive neck symptoms. Imaging was suggestive of a multinodular goiter with a large right thyroid nodule. Total thyroidectomy was planned, however intraoperative findings of a densely adherent thyroid with disruption of resection planes led to early termination of surgery. Biopsies obtained during surgery showed benign thyroid tissue with chronic lymphocytic thyroiditis, dense fibrous scar tissue, and benign lymph nodes, confirming the diagnosis of RT. The patient had minimal symptomatic improvement with chronic prednisone as high as 60 mg daily with tamoxifen at 30 mg twice a day. She subsequently received 4 doses of intravenous rituximab at 375 mg/m every 3 weeks, resulting in significant subjective improvement of her compressive symptoms as well as an objective decrease in size of the thyroid mass as seen on a subsequent computed tomography scan.

CONCLUSION

Evidence regarding etiology and management of RT is limited. We present a case of refractory RT treated with rituximab with resultant symptomatic improvement, thus providing further evidence for use of rituximab in resistant cases.

摘要

目的

里德尔甲状腺炎(RT)是一种罕见疾病,发病率高且治疗选择有限。我们描述了一例对皮质类固醇和他莫昔芬常规治疗耐药,但随后对利妥昔单抗有反应的病例。

方法

最初进行苏木精和伊红染色的手术病理检查以确诊,鉴于其与IgG4相关疾病的关联,在难治性RT情况下进行IgG4免疫染色和IgG4血清学检查。通过连续计算机断层扫描主观和客观地监测治疗反应。

结果

一名有桥本甲状腺炎病史的51岁女性出现颈部压迫症状。影像学检查提示为多结节性甲状腺肿,右侧有一个大的甲状腺结节。计划进行全甲状腺切除术,但术中发现甲状腺紧密粘连,切除平面中断,导致手术提前终止。手术中获取的活检显示为良性甲状腺组织,伴有慢性淋巴细胞性甲状腺炎、致密的纤维瘢痕组织和良性淋巴结,确诊为RT。患者服用高达每日60毫克的慢性泼尼松和每日两次30毫克的他莫昔芬后症状改善甚微。她随后每3周接受4剂静脉注射利妥昔单抗,剂量为375毫克/平方米,结果其压迫症状在主观上有显著改善,并且在随后的计算机断层扫描中可见甲状腺肿块大小在客观上有所减小。

结论

关于RT病因和治疗的证据有限。我们报告了一例用利妥昔单抗治疗的难治性RT病例,症状得到改善,从而为利妥昔单抗在耐药病例中的应用提供了进一步证据。

相似文献

5
Immunoglobulin G4-Related Thyroid Diseases.免疫球蛋白G4相关性甲状腺疾病
Eur Thyroid J. 2016 Dec;5(4):231-239. doi: 10.1159/000452623. Epub 2016 Dec 3.
6
A CASE OF RIEDEL'S THYROIDITIS.一例Riedel甲状腺炎病例。
Acta Endocrinol (Buchar). 2016 Jul-Sep;12(3):339-343. doi: 10.4183/aeb.2016.339.

本文引用的文献

1
Rituximab: a novel treatment for refractory Riedel's thyroiditis.利妥昔单抗:难治性里德耳甲状腺炎的一种新疗法。
Endocrinol Diabetes Metab Case Rep. 2018 Feb 9;2018. doi: 10.1530/EDM-17-0132. eCollection 2018.
2
Immunoglobulin G4-Related Thyroid Diseases.免疫球蛋白G4相关性甲状腺疾病
Eur Thyroid J. 2016 Dec;5(4):231-239. doi: 10.1159/000452623. Epub 2016 Dec 3.
5
Clinical review: Riedel's thyroiditis: a clinical review.临床综述:雷德尔甲状腺炎:临床综述。
J Clin Endocrinol Metab. 2011 Oct;96(10):3031-41. doi: 10.1210/jc.2011-0617. Epub 2011 Aug 10.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验